Chemotherapy Cachexia
The phase III trial found cannabis no better than placebo for appetite or quality of life in cancer cachexia — the 'munchies' didn't translate.
Digestive Emerging
What the research says
Cachexia is not just 'losing your appetite' — it's a metabolically driven wasting syndrome where the body burns muscle and fat even when eating. That distinction explains the disappointing trials. The largest, a phase III study of 243 advanced-cancer patients randomized to cannabis extract, THC, or placebo for six weeks, found no significant differences in appetite or quality of life — 73% of the cannabis-extract arm and 69% of placebo reported improved appetite, and an independent board stopped recruitment for futility.
A 2022 systematic review and meta-analysis (10 studies, 804 patients) reached the same conclusion: no significant benefit of cannabinoids for appetite, weight, or quality of life in cancer cachexia. It is a useful contrast to the 'Appetite Loss' page — THC clearly stimulates appetite in healthy people and in AIDS wasting, but cachexia's metabolic component is not fixed by appetite alone.
The honest caveats
If a cancer patient is losing weight, the priority is oncology and nutrition care — appetite stimulants (like megestrol), tailored nutrition, and treating the cause. Cannabinoids are not recommended for cachexia by current guidelines because the trials failed. For the nausea side, the picture is much better (see Chemotherapy Nausea) — but do not expect cannabis to reverse cachexia's weight and muscle loss.
Compounds to explore
These are the compounds — terpenes and cannabinoids — that the research connects to this condition. They are starting points for reading a COA or choosing a product, not prescriptions. Each has its own guide with more detail.
Cannabinoid THC Dronabinol and THC were the products tested head-to-head with placebo in the cachexia trials. Cannabinoid CBD Included in small amounts in the cannabis-extract trial arm.